Publications by authors named "Priya Rastogi"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,675,320

Total Likes

57,610

Extended Reach

2,210,393

Social Features

151
A
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña

June 2021

Videos about Article: user user user

3 5 148 8 92

View All Article and Social Media Activity
C
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, Danika L Lew, William E Barlow, Priya Rastogi

JAMA Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.
Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Priya Rastogi

J Natl Cancer Inst· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Erika P Hamilton, Sibylle Loibl, Thomas Bachelot, Michael Gnant, Naoki Niikura, Priya Rastogi

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials.
Julia Foldi, Neil Carleton, Stewart J Anderson, Priya Rastogi, Adrian Lee

J Natl Cancer Inst· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Charles E Geyer, Michael Untch, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas, Priya Rastogi

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
Priya Rastogi, Hanna Bandos, Peter C Lucas, Laura J van 't Veer, Jia-Perng J Wei

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
Mariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, Matthew P Goetz, Priya Rastogi

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Patricia A Ganz, Hanna Bandos, Tanja Španić, Sue Friedman, Volkmar Müller, Priya Rastogi

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Charles E Geyer, Joanne L Blum, Greg Yothers, Lina Asmar, Patrick J Flynn, Priya Rastogi

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Matthew P Goetz, Irfan Cicin, Laura Testa, Sara M Tolaney, Jens Huober, Priya Rastogi

NPJ Breast Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Priya Rastogi, Joyce O'Shaughnessy, Miguel Martin, Frances Boyle, Javier Cortes

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis, Priya Rastogi

J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong

J Natl Cancer Inst· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Priya Rastogi, Gong Tang, Saima Hassan, Charles E Geyer, Catherine A Azar

Breast Cancer Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, Marion T van Mackelenbergh, Michael Untch, Priya Rastogi

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E Geyer, Priya Rastogi

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
Stephen R D Johnston, Sara M Tolaney, Joyce O'Shaughnessy, Priya Rastogi, Nadia Harbeck

Lancet Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, Jordan C Ray, Emily C Craver, Priya Rastogi

Front Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Stephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, Priya Rastogi, Mario Campone

Lancet Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Charles E Geyer, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux

Breast Cancer Res Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Pterocarpus marsupium extract extends replicative lifespan in budding yeast.
Mitchell B Lee, Michael G Kiflezghi, Mitsuhiro Tsuchiya, Brian Wasko, Daniel T Carr, Priya Rastogi

Geroscience· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Charles E Geyer, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux

Breast Cancer Res Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis, Priya Rastogi

JAMA· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kevin Kalinsky, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Priya Rastogi

N Engl J Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis